Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

28
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration...
28
Diabetic Retinopathy01:27

Diabetic Retinopathy

51
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
51
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

677
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
677
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Diabetic Neuropathy01:22

Diabetic Neuropathy

49
DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
49
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

1.3K
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The personalized approach to rituximab treatment in membranous nephropathy: a multi-center randomized controlled trial.

EClinicalMedicine·2025
Same author

More on Selpercatinib and Pseudo-Decreases in Kidney Function.

The New England journal of medicine·2025
Same author

[Acute kidney injury in cancer patients receiving immune checkpoint inhibitor therapy-shared guidelines of FITC/SFNDT].

Bulletin du cancer·2024
Same author

Renal involvement in solid cancers: epidemiological, clinical and histological characteristics study of 154 onconephrology patients.

BMC nephrology·2024
Same author

The predictive performance of the ANCA renal risk score in patients over 65 years of age with renal ANCA-associated vasculitis.

Clinical kidney journal·2024
Same author

Thrombotic Microangiopathy After Long-Lasting Treatment by Gemcitabine: Description, Evolution and Treatment of a Rare Case.

Journal of medical cases·2024

Related Experiment Video

Updated: Apr 28, 2026

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

796

[Diabetic nephropathy: emerging treatments].

Victor Gueutin1, Marion Gauthier1, Maud Cazenave1

  • 1Service de néphrologie, groupe hospitalier de la Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France.

Nephrologie & Therapeutique
|June 19, 2014
PubMed
Summary

Silymarin shows promise in reducing key markers of diabetic nephropathy, such as albumin and TNF-α. Further large-scale studies are needed to confirm its role in treating this kidney disease.

Keywords:
Agents nouveauxChronic kidney diseaseDiabetes mellitusDiabetic nephropathy therapyDiabète sucréMaladie rénale chroniqueNovel agentsTraitement de la néphropathie diabétique

More Related Videos

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

1.1K
Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature
10:07

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature

Published on: December 26, 2017

15.0K

Related Experiment Videos

Last Updated: Apr 28, 2026

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

796
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

1.1K
Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature
10:07

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature

Published on: December 26, 2017

15.0K

Area of Science:

  • Nephrology
  • Endocrinology
  • Biochemistry

Background:

  • Diabetic nephropathy is a primary cause of end-stage renal disease globally.
  • Current treatments focus on hyperglycemia, blood pressure, and proteinuria.
  • Newer strategies since 2000 target glucose's biochemical effects on kidneys.

Purpose of the Study:

  • To evaluate the potential of novel therapeutic agents for diabetic nephropathy.
  • To assess the efficacy of silymarin in managing diabetic nephropathy.

Main Methods:

  • Review of emerging therapeutic strategies for diabetic nephropathy.
  • Analysis of silymarin's impact on specific biochemical markers in patients.

Main Results:

  • Silymarin demonstrated a reduction in urinary albumin excretion.
  • Silymarin decreased levels of tumor necrosis factor-alpha (TNF-α) and malondialdehyde.
  • These findings suggest silymarin's potential therapeutic benefits.

Conclusions:

  • Silymarin may be a valuable addition to the treatment of diabetic nephropathy.
  • Larger clinical trials are necessary to validate silymarin's utility for diabetic kidney disease.